Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of E7389 in Pretreated Advanced/Metastatic Soft Tissue Sarcoma
2005-004272-20Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in soft tissue sarcoma (STS), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
eribulin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2005-004272-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004272-20.